| 5.97 -0.15 (-2.45%) | 08-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.42 | 1-year : | 8.67 |
| Resists | First : | 6.36 | Second : | 7.42 |
| Pivot price | 5.84  |
|||
| Supports | First : | 5.51 |
Second : | 5 |
| MAs | MA(5) : | 6.1 |
MA(20) : | 5.74 |
| MA(100) : | 4.41 |
MA(250) : | 3.47 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 73.2 |
D(3) : | 81.9 |
| RSI | RSI(14): 64.6 |
|||
| 52-week | High : | 6.36 | Low : | 1.21 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ FOCL ] has closed below upper band by 39.8%. Bollinger Bands are 51.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.25 - 6.3 | 6.3 - 6.33 |
| Low: | 5.87 - 5.92 | 5.92 - 5.96 |
| Close: | 5.9 - 5.98 | 5.98 - 6.04 |
EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors. In contrast, the UDS division concentrates on the entire lifecycle—from development and marketing to manufacturing and servicing—of medical instruments used for the minimally invasive diagnosis and treatment of various urological disorders, particularly urinary stones and other related clinical indications. This enterprise was founded on December 3, 1979, and its corporate headquarters are located in Vaulx-en-Velin, France.
Fri, 29 May 2026
New FocalTherics name marks EDAP’s exclusive focus on robotic focal therapy - Stock Titan
Fri, 29 May 2026
EDAP changes name to FocalTherics, new ticker FOCL June 1 - Investing.com
Fri, 29 May 2026
EDAP Announces Corporate Name Change to FocalTherics™ to - GlobeNewswire
Thu, 28 May 2026
EDAP Q4 2025 Earnings: Wider-than-Expected Loss Weighs on Shares - Margin Compression Risk - dars.gov.et
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 37 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 6.1 (%) |
| Held by Institutions | 38.8 (%) |
| Shares Short | 234 (K) |
| Shares Short P.Month | 135 (K) |
| EPS | -0.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.27 |
| Profit Margin | -41.8 % |
| Operating Margin | -41.4 % |
| Return on Assets (ttm) | -21.1 % |
| Return on Equity (ttm) | -130.5 % |
| Qtrly Rev. Growth | 24.7 % |
| Gross Profit (p.s.) | 0.85 |
| Sales Per Share | 1.97 |
| EBITDA (p.s.) | -0.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -7.29 |
| PEG Ratio | 0 |
| Price to Book value | 22.11 |
| Price to Sales | 3.02 |
| Price to Cash Flow | -15.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|